Cited 0 time in
Comparative evaluation of non-invasive tests for risk stratification for cause specific mortality in at-risk population of hepatic fibrosis
| DC Field | Value | Language |
|---|---|---|
| dc.contributor.author | Park, Huiyul | - |
| dc.contributor.author | Yoon, Eileen L. | - |
| dc.contributor.author | Kim, Mimi | - |
| dc.contributor.author | Kim, Hye-Lin | - |
| dc.contributor.author | Kim, Mi Kyung | - |
| dc.contributor.author | Kim, Yu-Mi | - |
| dc.contributor.author | Jun, Dae Won | - |
| dc.date.accessioned | 2024-11-28T08:36:35Z | - |
| dc.date.available | 2024-11-28T08:36:35Z | - |
| dc.date.issued | 2024-03 | - |
| dc.identifier.issn | 2045-2322 | - |
| dc.identifier.issn | 2045-2322 | - |
| dc.identifier.uri | https://scholarworks.bwise.kr/hanyang/handle/2021.sw.hanyang/195466 | - |
| dc.description.abstract | Our study aimed to conduct a comparative evaluation of various noninvasive tests (NITs) for risk stratification in at-risk population for non-alcoholic fatty liver disease (NAFLD), focusing on cardiovascular and liver-related mortality. A total of 21,715 adults aged 40 years and older were enrolled at baseline. The mean follow-up period was 12.39 years. Three types of NITs (fibrosis-4 index [FIB-4], NAFLD fibrosis score [NFS], and steatosis-associated fibrosis estimator [SAFE] score) were used. When using the low cut-off as a 'rule-out' strategy, there were no significant differences in cardiovascular mortality between the 'rule-out' (low-risk) group and the 'rule-in' (intermediate- or high-risk) group based on FIB-4 (aHR = 1.029, P = 0.845) or NFS (aHR = 0.839, P = 0.271) classification. However, the SAFE score exhibited higher sensitivity in predicting cardiovascular mortality compared to FIB-4 or NFS (73.3% in SAFE score vs. 29.6% in FIB-4 or 21.3% in NFS). Only the SAFE score could effectively differentiate the risk between low- and intermediate- or high-risk groups for all types of mortality (all P values for aHR < 0.001). The low cutoff value of the SAFE score discriminated not only liver-related mortality but also identified the cardiovascular high-risk group in the community cohort. | - |
| dc.format.extent | 10 | - |
| dc.language | 영어 | - |
| dc.language.iso | ENG | - |
| dc.publisher | Nature Publishing Group | - |
| dc.title | Comparative evaluation of non-invasive tests for risk stratification for cause specific mortality in at-risk population of hepatic fibrosis | - |
| dc.type | Article | - |
| dc.publisher.location | 영국 | - |
| dc.identifier.doi | 10.1038/s41598-024-56085-3 | - |
| dc.identifier.scopusid | 2-s2.0-85188628826 | - |
| dc.identifier.wosid | 001195454400102 | - |
| dc.identifier.bibliographicCitation | Scientific Reports, v.14, no.1, pp 1 - 10 | - |
| dc.citation.title | Scientific Reports | - |
| dc.citation.volume | 14 | - |
| dc.citation.number | 1 | - |
| dc.citation.startPage | 1 | - |
| dc.citation.endPage | 10 | - |
| dc.type.docType | Article | - |
| dc.description.isOpenAccess | Y | - |
| dc.description.journalRegisteredClass | scie | - |
| dc.description.journalRegisteredClass | scopus | - |
| dc.relation.journalResearchArea | Science & Technology - Other Topics | - |
| dc.relation.journalWebOfScienceCategory | Multidisciplinary Sciences | - |
| dc.subject.keywordPlus | LIVER | - |
| dc.subject.keywordPlus | PATHWAY | - |
| dc.subject.keywordPlus | NAFLD | - |
| dc.subject.keywordAuthor | At-risk population | - |
| dc.subject.keywordAuthor | Fibrosis-4 index | - |
| dc.subject.keywordAuthor | Hepatic and extrahepatic mortality | - |
| dc.subject.keywordAuthor | Non-alcoholic fatty liver disease | - |
| dc.subject.keywordAuthor | SAFE score | - |
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.
222, Wangsimni-ro, Seongdong-gu, Seoul, 04763, Korea+82-2-2220-1366
COPYRIGHT © 2024 HANYANG UNIVERSITY.
Certain data included herein are derived from the © Web of Science of Clarivate Analytics. All rights reserved.
You may not copy or re-distribute this material in whole or in part without the prior written consent of Clarivate Analytics.
